IBJNews

Court upholds Lilly patent on cancer drug Alimta

Back to TopCommentsE-mailPrintBookmark and Share

Indianapolis-based Eli Lily and Co. said a federal court judge has upheld a patent protecting one of its best-selling drugs, the cancer treatment Alimta.

A trial on the drug's compound patent, which protects its chemical makeup, started Nov. 8 and ended Monday with a ruling from the U.S. District Court for the District of Delaware, Lilly said. Generic drugmaker Teva Pharmaceuticals Industries Ltd. had challenged the patent, which protects Alimta until July 2016.

Alimita was Lilly's third-best-selling drug in the third quarter, trailing only the antipsychotic Zyprexa and the antidepressant Cymbalta. Revenue from Alimta climbed 21 percent, to $560.3 million, in the quarter, as sales in Japan rose. Alimta rang up $1.64 billion in sales during the first three quarters of 2010.

It was a welcome court win after a difficult few months for Lilly, which is facing a wave of patent expirations in coming years.

In August, a federal judge in New Jersey ruled that the company's method-of-use patent for attention deficit hyperactivity drug Strattera is invalid; Lilly is appealing that decision.  The previous month, a federal appeals court upheld a ruling that invalidated a patent on cancer drug Gemzar, which generates $750 million in U.S. sales each year.

A generic version of Gemzar launched Monday.

Gemzar is the first of several blockbuster Lilly drugs that will see their patents expire by 2013. Generic versions of Zyprexa, Cymbalta, Evista and Strattera could zap nearly half of Lilly's current sales, putting great pressure on the company to find new drugs to take their place.

Alimta is a chemotherapy drug used to treat advanced nonsquamous non-small cell lung cancer and malignant pleural mesothelioma, a cancer that affects the inside lining of the chest cavity.

Lilly said last month its third-quarter profit jumped 38 percent to $1.3 billion, as international sales climbed. But, aside from court challenges, the company also faces patent expirations for some of its key products. That includes Zyprexa next year and Cymbalta in 2013.

Analysts who follow Lilly question how it will make up for the lost revenue. Company leaders have repeatedly expressed confidence in their pipeline of drugs under development, and they also point to growth opportunities in the animal health business and emerging international markets.

 

 

 


 
 

ADVERTISEMENT

Post a comment to this story

COMMENTS POLICY
We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
 
You are legally responsible for what you post and your anonymity is not guaranteed.
 
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
 
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
 
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.
 

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
  1. Really, taking someone managing the regulation of Alcohol and making himthe President of an IVY Tech regional campus. Does he have an education background?

  2. Jan, great rant. Now how about you review the report and offer rebuttal of the memo. This might be more conducive to civil discourse than a wild rant with no supporting facts. Perhaps some links to support your assertions would be helpful

  3. I've lived in Indianapolis my whole and been to the track 3 times. Once for a Brickyard, once last year on a practice day for Indy 500, and once when I was a high school student to pick up trash for community service. In the past 11 years, I would say while the IMS is a great venue, there are some upgrades that would show that it's changing with the times, just like the city is. First, take out the bleachers and put in individual seats. Kentucky Motor Speedway has individual seats and they look cool. Fix up the restrooms. Add wi-fi. Like others have suggested, look at bringing in concerts leading up to events. Don't just stick with the country music genre. Pop music would work well too I believe. This will attract more young celebrities to the Indy 500 like the kind that go to the Kentucky Derby. Work with Indy Go to increase the frequency of the bus route to the track during high end events. That way people have other options than worrying about where to park and paying for parking. Then after all of this, look at getting night lights. I think the aforementioned strategies are more necessary than night racing at this point in time.

  4. Talking about congestion ANYWHERE in Indianapolis is absolutely laughable. Sure you may have to wait in 5 minutes of traffic to travel down BR avenue during *peak* times. But that is absolutely nothing compared to actual big cities. Indy is way too suburban to have actual congestion problems. So please, never bring up "congestion" as an excuse to avoid development in Indianapolis. If anything, we could use a little more.

  5. Oh wait. Never mind.

ADVERTISEMENT